Remove Hormones Remove Insulin Remove Life Science Remove Pharmacy
article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the fourth quarter and decreased 56.7 from $289.36.

Sales 52
article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. mg and 2.4